- Design
- randomised, double-blind, placebo-controlled trial, 8 weeks
- Population
- 60 adults aged 40 to 75 with mild to moderate knee osteoarthritis
- Primary outcome
- total Western Ontario and McMaster Universities Osteoarthritis Index score and subscales
- Effect
- significant reduction in index, pain, stiffness, visual analogue score and high-sensitivity C-reactive protein (P < .05); magnitudes not reported
Patients ask about Boswellia serrata constantly, and the evidence they are asking about is mostly small trials of proprietary extracts. This one randomised 60 adults aged 40 to 75 with mild to moderate knee osteoarthritis to 100 mg daily of a standardised extract or placebo for eight weeks, double-blind, with the osteoarthritis index and a visual analogue pain score measured at days 7, 15, 30 and 60.
The reported findings are consistently in favour: significant reductions against placebo in the total index score and in the pain, stiffness and physical function subscales, a lower visual analogue score, and a fall in high-sensitivity C-reactive protein. Separation was reported as early as day 7. The extract was described as well tolerated over the eight weeks.
What is missing is the part a clinician needs. No effect size is given for any outcome — only that the differences were significant at P < .05. A statistically significant difference on an osteoarthritis index in 60 patients can be anything from a change a patient would notice to one well below the minimal clinically important difference, and without the numbers there is no way to tell which this was. The biochemical outcome carries the same problem.
So the honest position to take with a patient is narrow: a small randomised trial of one specific standardised preparation reported benefit over eight weeks with no safety concerns raised, the magnitude of that benefit was not published, and results from one proprietary extract do not transfer to other Boswellia products on the shelf. That last point matters most in India, where these are sold without standardisation and a patient buying Boswellia is not necessarily buying what was tested.
- Tell patients that benefit was reported but its size was not published, so it cannot be compared with standard analgesia
- Explain that results from one standardised extract do not transfer to other Boswellia products, which vary widely in content
- Do not substitute this for established osteoarthritis management — exercise, weight management and analgesia as indicated
- Ask specifically about herbal and Ayurvedic preparations at review; patients often do not report them as medication
- Note the eight-week duration: nothing here speaks to longer-term efficacy or safety
Why it matters
This is the supplement patients are already taking, and the evidence they cite is rarely read closely enough to see what it omits.
Don't overread it
Sixty patients over eight weeks, with no effect size published, cannot support recommending this in place of established treatment.
The statistics, in plain English
P < .05 tells you a difference is unlikely to be chance; it tells you nothing about whether the difference matters. With 60 participants the trial could only detect a fairly large effect, so a significant result here is not a small one — but without the actual scores and their spread, that cannot be checked. Reporting significance without magnitude is the single most common way a trial abstract becomes unusable, and the reader should treat it as a reason for caution rather than an oversight.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for rheumatology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free